CCL24 Blockade with Nebokitug Modulates Inflammation and Fibrosis Signatures in Primary Sclerosing Cholangitis
- 1Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel
Abstract
Background and Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation, fibrosis, and innate immune dysregulation, with no approved therapies. Nebokitug (CM-101), a humanized monoclonal antibody targeting CCL24, demonstrated anti-inflammatory, anti-fibrotic, and anti-cholestatic activity in a Phase 2 clinical trial in patients with PSC. We performed comprehensive serum proteomic analyses to characterize the mechanistic effects of the CCL24 blockade following treatment with nebokitug. Methods: Serum samples from study patients treated with nebokitug 10 mg/kg (n = 21), 20 mg/kg (n = 27), or placebo (n = 18) were analyzed using the Olink Explore 3072 proximity extension assay. Differential protein expression, pathway enrichment, and liver-specific proteome analyses were performed. Proteins corresponding to four PSC-specific gene expression programs (GEPs), identified previously by single-cell liver transcriptomics, were evaluated. An Elastic Net machine learning model was trained to classify treatment response defined by changes in Enhanced Liver Fibrosis (ELF) scores, liver stiffness measurements, and PRO-C3 test results. Results: Nebokitug induced dose-dependent modulation of proteins involved in chemotaxis, leukocyte recruitment, extracellular matrix remodeling, cytokine signaling, and collagen organization. Proteins representing PSC-specific GEPs related to fibrosis, extracellular matrix remodeling, macrophage activation, myofibroblast biology, and immune activation and were reduced following nebokitug treatment, particularly in patients with moderate-to-advanced disease treated with the 20 mg/kg dose. A machine-learning model accurately identified responders (mean AUROC = 0.92), with liver-specific proteins representing the dominant predictive signature. Consistent with this finding, analysis of liver-specific proteins demonstrated clear separation between responders and non-responders in the 20 mg/kg group (p = 0.0001), further linking treatment response to modulation of liver-specific biology. Conclusions: Comprehensive proteomic profiling demonstrates that a CCL24 blockade with nebokitug modulates key biological pathways driving PSC. These findings provide mechanistic support for nebokitug’s effect in PSC and further validate CCL24 as a promising therapeutic target in this indication.
Related
- Paradoxical hepcidin–iron dysregulation in primary sclerosing cholangitis
- Muscle-lung crosstalk in COPD: how exercise training modulates protein metabolism and inflammation in experimental COPD models
- Sphingosine-1-Phosphate Restrains Foamy Macrophage Formation and Modulates Inflammation in Multidrug-Resistant Tuberculosis
- A novel CXCL8(3-72) K11R/G31P-BPI₂₃₃ hybrid protein modulates neutrophil-driven inflammation and protects against carbapenem-resistant Acinetobacter baumannii infection.
- Molecular signatures of genetically defined jugular nociceptors and their responses to allergic airway inflammation
BibTeX
@article{aricha2026ccl24,
title = {{CCL24 Blockade with Nebokitug Modulates Inflammation and Fibrosis Signatures in Primary Sclerosing Cholangitis}},
author = {Revital Aricha and Tom Snir and John Lawler and Adi Mor},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15201853},
url = {https://www.mdpi.com/2073-4409/15/20/1853},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CCL24 Blockade with Nebokitug Modulates Inflammation and Fibrosis Signatures in Primary Sclerosing Cholangitis
AU - Revital Aricha
AU - Tom Snir
AU - John Lawler
AU - Adi Mor
PY - 2026
DA - 2026/10/12
JO - Cells
DO - 10.3390/cells15201853
UR - https://www.mdpi.com/2073-4409/15/20/1853
AB - Background and Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation, fibrosis, and innate immune dysregulation, with no approved therapies. Nebokitug (CM-101), a humanized monoclonal antibody targeting CCL24, demonstrated anti-inflammatory, anti-fibrotic, and anti-cholestatic activity in a Phase 2 clinical trial in patients with PSC. We performed comprehensive serum proteomic analyses to characterize the mechanistic effects of the CCL24 blockade following treatment with nebokitug. Methods: Serum samples from study patients treated with nebokitug 10 mg/kg (n = 21), 20 mg/kg (n = 27), or placebo (n = 18) were analyzed using the Olink Explore 3072 proximity extension assay. Differential protein expression, pathway enrichment, and liver-specific proteome analyses were performed. Proteins corresponding to four PSC-specific gene expression programs (GEPs), identified previously by single-cell liver transcriptomics, were evaluated. An Elastic Net machine learning model was trained to classify treatment response defined by changes in Enhanced Liver Fibrosis (ELF) scores, liver stiffness measurements, and PRO-C3 test results. Results: Nebokitug induced dose-dependent modulation of proteins involved in chemotaxis, leukocyte recruitment, extracellular matrix remodeling, cytokine signaling, and collagen organization. Proteins representing PSC-specific GEPs related to fibrosis, extracellular matrix remodeling, macrophage activation, myofibroblast biology, and immune activation and were reduced following nebokitug treatment, particularly in patients with moderate-to-advanced disease treated with the 20 mg/kg dose. A machine-learning model accurately identified responders (mean AUROC = 0.92), with liver-specific proteins representing the dominant predictive signature. Consistent with this finding, analysis of liver-specific proteins demonstrated clear separation between responders and non-responders in the 20 mg/kg group (p = 0.0001), further linking treatment response to modulation of liver-specific biology. Conclusions: Comprehensive proteomic profiling demonstrates that a CCL24 blockade with nebokitug modulates key biological pathways driving PSC. These findings provide mechanistic support for nebokitug’s effect in PSC and further validate CCL24 as a promising therapeutic target in this indication.
SN - 2073-4409
ER -